Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II LP-003 in adults with moderate-to-severe seasonal allergic rhinitis
ChiCTR2300073073Phase 2Recruiting
- Sponsor
- Beijing Shijitan Hospital
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of LP-003 in seasonal allergic rhinitis (SAR) (3 arms), sponsored by Beijing Shijitan Hospital. Primary endpoints: Total nasal symptom score and Injection site examination. Started Mar 2023; status: recruiting.
02
Drugs
LP-003
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on ChiCTR2300073073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073073.